Table 3.
Clinical and laboratory factors at the onset of a microbiologically documented infection associated with tocilizumab use according to logistic univariate and multivariable analyses.
| Variable | OR[95%CI] | p-value | ⁎⁎aOR[95%CI] | p-value |
|---|---|---|---|---|
| Clinical presentation of infection | ||||
| Hypotension | 1.57 [0.53-4.59] |
0.408 | ||
| Body temperature >38°C | 1.082 [0.35-3.32] |
0.890 | ||
| Body temperature <36°C | 7.92e-8 [0.00-inf] |
0.992 | ||
| Oxygen desaturation | 2.82 [0.72-11.01] |
0.136 | ||
| Laboratory parameters at infection | ||||
| Δ SOFA ≥ 2 | 1.38 [0.31-6.16] |
0.672 | ||
| WBC increase* | 1.67 [0.58-4.85] |
0.343 | ||
| Neutrophils increase* | 1.21 [0.42-3.47] |
0.724 | ||
| CRP increase* | 0.23 [0.08-0.71] |
0.011 | 0.18 [0.04-0.77] |
0.021 |
| PCT > 1ug/L | 0.23 [0.04-1.19] |
0.080 | 0.22 [0.03-1.51] |
0.124 |
Table legend: 95%CI: 95% confidence interval; aOR: adjusted odds ratio; OR: odds ratio, WBC: white blood cell count.
⁎
as compared with values measured in the 24-48 hours before infection onset.
⁎⁎
The multivariable model was further adjusted for WBC count and steroid use.